Screener
Biodesix, Inc. BDSX Q2 2026 earnings
Reported August 5, 2026 · After market close
Revenue$26.9MBeat by $835.5K
EPS-$0.71Beat by $0.19
Revenue estimate$26.0M
EPS estimate-$0.90
“Biodesix delivered another strong quarter, highlighted by 34% revenue growth, 42% growth in Diagnostic Testing revenue, and gross margins, which increased to 82%. Our performance reflects continued adoption of our blood-based lung diagnostics, expanding reimbursement coverage, and improving sales force productivity. Diagnostic testing volumes grew 38% year-over-year while operating expenses excluding direct costs increased only 7%, demonstrating meaningful operating leverage and a 56% improvement in Adjusted EBITDA.”
Next report
Nov 2, 2026 (in 2 months)Revenue estimate$27.6M
EPS estimate-$0.74
Valuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Biodesix, Inc. report Q2 2026 earnings?
- Biodesix, Inc. (BDSX) reported Q2 2026 earnings on August 5, 2026 after market close.
- What were Biodesix, Inc.'s Q2 2026 revenue and EPS?
- Biodesix, Inc. reported revenue of $26.9M and eps of $-0.71 for Q2 2026.
- Did Biodesix, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $26.0M by $835.5K. EPS beat the consensus estimate of $-0.90 by $0.19.
- How did Biodesix, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 34.2% from $20.0M a year earlier and eps grew 55.6% from $-1.60.
- Where can I find Biodesix, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-335010) and the 10-Q periodic report (0001193125-26-335036) directly on SEC EDGAR. The filing index links above go to sec.gov.
